An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia.

Sakamoto K, Jin Z, Koan D, Fujimoto R, Yokoyama R, Asano S, Ishimura R, Nunomura K, Lin B, Sugiyama D, Shiba H, Nishizawa N, Nakagawa S, Ago Y.

Open source

DOI: 10.1248/bpb.b26-00222
Published: 2026-01-01
Container: Biol Pharm Bull
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1248/bpb.b26-00222,
  title = {An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia.},
  author = {Sakamoto K and  Jin Z and  Koan D and  Fujimoto R and  Yokoyama R and  Asano S and  Ishimura R and  Nunomura K and  Lin B and  Sugiyama D and  Shiba H and  Nishizawa N and  Nakagawa S and  Ago Y.},
  year = {2026},
  journal = {Biol Pharm Bull},
  doi = {10.1248/bpb.b26-00222},
  url = {https://doi.org/10.1248/bpb.b26-00222}
}

RIS

TY  - JOUR
TI  - An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia.
AU  - Sakamoto K
AU  -  Jin Z
AU  -  Koan D
AU  -  Fujimoto R
AU  -  Yokoyama R
AU  -  Asano S
AU  -  Ishimura R
AU  -  Nunomura K
AU  -  Lin B
AU  -  Sugiyama D
AU  -  Shiba H
AU  -  Nishizawa N
AU  -  Nakagawa S
AU  -  Ago Y.
PY  - 2026
JO  - Biol Pharm Bull
DO  - 10.1248/bpb.b26-00222
UR  - https://doi.org/10.1248/bpb.b26-00222
ER  -

APA

K, S., Z, J., D, K., R, F., R, Y., S, A., R, I., K, N., B, L., D, S., H, S., N, N., S, N., & Y., A. (2026). An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in Schizophrenia.. Biol Pharm Bull. https://doi.org/10.1248/bpb.b26-00222

Source records

europe-pmc · retrieved 2026-09-26T10:02:45.079Z